WallStSmart

Linde plc Ordinary Shares (LIN)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 31% more annual revenue ($44.56B vs $33.99B). LIN leads profitability with a 20.3% profit margin vs 15.0%. TMO appears more attractively valued with a PEG of 1.76. TMO earns a higher WallStSmart Score of 59/100 (C).

LIN

Buy

56

out of 100

Grade: C

Growth: 6.0Profit: 8.0Value: 7.3Quality: 5.0
Piotroski: 3/9Altman Z: 1.49

TMO

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LINSignificantly Overvalued (-396.3%)

Margin of Safety

-396.3%

Fair Value

$99.21

Current Price

$492.34

$393.13 premium

UndervaluedFair: $99.21Overvalued
TMOSignificantly Overvalued (-27.5%)

Margin of Safety

-27.5%

Fair Value

$384.82

Current Price

$490.77

$105.95 premium

UndervaluedFair: $384.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LIN4 strengths · Avg: 8.8/10
Market CapQuality
$222.36B10/10

Mega-cap, among the largest globally

Profit MarginProfitability
20.3%9/10

Keeps 20 of every $100 in revenue as profit

Operating MarginProfitability
28.2%8/10

Strong operational efficiency at 28.2%

Free Cash FlowQuality
$1.57B8/10

Generating 1.6B in free cash flow

TMO3 strengths · Avg: 8.3/10
Market CapQuality
$182.14B9/10

Large-cap with strong market position

Operating MarginProfitability
21.2%8/10

Strong operational efficiency at 21.2%

Free Cash FlowQuality
$2.99B8/10

Generating 3.0B in free cash flow

Areas to Watch

LIN4 concerns · Avg: 3.3/10
PEG RatioValuation
2.294/10

Expensive relative to growth rate

P/E RatioValuation
32.9x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-9.4%2/10

Earnings declined 9.4%

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

P/E RatioValuation
27.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : LIN

The strongest argument for LIN centers on Market Cap, Profit Margin, Operating Margin. Profitability is solid with margins at 20.3% and operating margin at 28.2%.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : LIN

The primary concerns for LIN are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

LIN profiles as a mature stock while TMO is a value play — different risk/reward profiles.

TMO carries more volatility with a beta of 0.97 — expect wider price swings.

TMO is growing revenue faster at 7.2% — sustainability is the question.

TMO generates stronger free cash flow (3.0B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (59/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Linde plc Ordinary Shares

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

Linde plc is a multinational chemical company. It is the largest industrial gas company by market share and revenue. It serves customers in the healthcare, petroleum refining, manufacturing, food, beverage carbonation, fiber-optics, steel making, aerospace, chemicals, electronics and water treatment industries. The company's primary business is the manufacturing and distribution of atmospheric gases, including oxygen, nitrogen, argon, rare gases, and process gases, including carbon dioxide, helium, hydrogen, electronic gases, specialty gases, and acetylene.

Visit Website →

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?